Heparin Binding by Fibronectin Module III-13 Involves Six Discontinuous Basic Residues Brought Together to Form a Cationic Cradle (*)

  1. Thomas F. Busby,
  2. W. Scott Argraves,
  3. Shelesa A. Brew,
  4. Igor Pechik(1)(2),
  5. Gary L. Gilliland(1)(2) and
  6. Kenneth C. Ingham(§)
  1. From the (1) Holland Laboratory, American Red Cross, the Center for Advanced Research in Biotechnology of the Maryland Biotechnology Institute, and the
  2. (2) National Institute of Standards and Technology, Rockville, Maryland 20855
  1. § To whom correspondence should be addressed:
    American Red Cross, 15601 Crabbs Branch Way, Rockville, MD 20855.
    Tel.: 301-738-0731; Fax: 301-738-0794.

Abstract

The thirteenth type III domain of fibronectin binds heparin almost as well as fibronectin itself and contains a so-called heparin-binding consensus sequence, Arg6-Arg7-Ala8-Arg9 (residues 1697-1700 in plasma fibronectin). Barkalow and Schwarzbauer (Barkalow, F. J., and Schwarzbauer, J. E. (1991) J. Biol. Chem. 266, 7812-7818) showed that mutation of Arg6-Arg7 in domain III-13 of recombinant truncated fibronectins abolished their ability to bind heparin-Sepharose. However, synthetic peptides containing this sequence have negligible affinity for heparin (Ingham, K. C., Brew, S. A., Migliorini, M. M., and Busby, T. F.(1993) Biochemistry 32, 12548-12553). We generated a three-dimensional model of fibronectin type III-13 based on the structure of a homologous domain from tenascin. The model places ArgGraphic, LysGraphic, and ArgGraphic parallel to and in close proximity to the Arg6-Arg7-Ala8-Arg9 motif, suggesting that these residues may also contribute to the heparin-binding site. Domain III-13 and six single-site mutants containing Ser in place of each of the above-mentioned basic residues were expressed in Escherichia coli. All of the purified mutant domains melted reversibly with a T m near that of the wild type indicating that they were correctly folded. When fluorescein-labeled heparin was titrated at physiological ionic strength, the wild type domain increased the anisotropy in a hyperbolic fashion with a KGraphic of 5-7 μM, close to that of the natural domain obtained by proteolysis of fibronectin. The R54S mutant bound 3-fold weaker and the remaining mutants bound at least 10-fold weaker than wild type. The results point out that the Arg6-Arg7-Ala8-Arg9 consensus sequence by itself has little affinity for heparin under physiological conditions, even when presented in the context of a folded domain. Thus, the heparin-binding site in fibronectin is more complex than previously realized. It is formed by a cluster of 6 positively charged residues that are remote in the sequence but brought together on one side of domain III-13 to form a “cationic cradle” into which the anionic heparin molecule could fit.

Footnotes

  • * This work was supported in part by National Institutes of Health Grants HL21791 and HL44336. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • 1 The abbreviations used are:

    GAGs

    glycosaminoglycans

    PCR

    polymerase chain reaction.

    • Received May 15, 1995.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement